Business Wire

HCL-TECHNOLOGIES

27.2.2020 17:17:12 CET | Business Wire | Press release

Share
HCL Foundation Announces Winners of Fifth Edition of HCL Grant

HCL Foundation (HCLF), the Corporate Social Responsibility (CSR) arm of HCL Technologies, today announced the recipients of the fifth edition of HCL Grant in the presence of Padma Bhushan, Mr. Kapil Dev, a legend in the global world of cricket and former captain of the Indian Cricket team.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200227005709/en/

HCL Grant is one of the biggest and most coveted institutionalized CSR grants in India that aims to recognize the rise of the Fifth Estate - the Non-Governmental Organizations (NGOs).

The evening was also graced by Mr. Shiv Nadar, Founder & Chairman, HCL, Ms. Roshni Nadar Malhotra, Vice Chairperson of HCL Technologies and the Chairperson of its CSR committee, and Mr. Prateek Aggarwal, Chief Financial Officer, HCL Technologies along with senior dignitaries, officials, NGO-partners and HCL leadership.

HCL Grant 2020 witnessed three NGOs across the categories of Education, Healthcare and Environment receiving a grant of ₹5 crores each. The remaining six finalists across the three categories also received ₹25 lakhs each, taking the overall Grant to ₹16.5 crore.

The finalists and the winners were selected by an eminent jury, which was chaired by Ms. Robin Abrams, Member of the Board, HCL Technologies.

Recipients of HCL Grant 2020:

  • Environment- The 2020 HCL Grant winner in this category is Under The Mango Tree Society.
    Project Location: 4 districts (Gujarat, Maharashtra and Madhya Pradesh)
  • Healthcare- The 2020 HCL Grant winner in this category is Operation ASHA.
    Project Location: Kullu (Himachal Pradesh)
  • Education- The 2020 HCL Grant winner in this category is Bal Raksha Bharat.
    Project Location: Leh (Ladakh) and Budgam (J&K)

“It is extremely important to bring equal opportunities to people coming from every strata of the society. Health, Education and Environment are one of the most important pillars towards India’s development goals and I am highly impressed with the kind of impact these NGOs are bringing in the rural communities. Also, the robustness of the identification process is something I have not witnessed before. I congratulate both HCL as well the winners and finalists for the phenomenal work they are doing in their respective fields,” Mr. Kapil Dev said while addressing the audience at the event.

Excluding the current grant, HCL Grant has already disbursed ₹51.5 crores (US$ 7.4Mn) to benefit nearly 500,000 people and its supported projects aim to cover over a million people spread across 7,500 villages across 13 States and one Union Territory in the country.

“HCL Foundation is our long-term commitment for social development and today it has improved over 1.5 million lives across our country. Our collaborative model allows us to support communities with critical concerns needing immediate attention and HCL Grant is a prime example of the same. I am proud to say that today the improvements we have been able to drive together with the HCL Grant partner NGOs is not just in terms of immediate impact on beneficiary lives, but also about ensuring long-term sustainable change by influencing state and government policies,” said Ms. Roshni Nadar Malhotra, Vice-Chairperson, HCL Technologies and Chairperson, CSR Committee, HCL Technologies.

Ms. Nidhi Pundhir, Director HCL Foundation, said, “This is a very special year for us as we complete half a decade of empowering the NGOs that are committed to ushering change. This annual HCL Grant event is a culmination of our year-long efforts to identify partners who have the potential to achieve the maximum impact through their social development projects.. We are truly honored to have received applications from all parts of the country and my heartiest congratulations to the winning NGOs for giving us the opportunity to partner with them and support ideas for impactful positive change.”

HCL Foundation also released the compendium of the previous year’s finalists and winning NGOs, named “Fifth Estate – NGOs Transforming Rural India in Environment, Health and Education”.

For more information please visit www.hclfoundation.org/hcl-grant .

Link:

ClickThru

Social Media:

https://www.facebook.com/HCLTechnologies/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye